Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,971 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort.
Kaaks R, Sookthai D, Hemminki K, Krämer A, Boeing H, Wirfält E, Weiderpass E, Overvad K, Tjønneland A, Olsen A, Peeters PH, Bueno-de-Mesquita HB, Panico S, Pala V, Vineis P, Quirós JR, Ardanaz E, Sánchez MJ, Chirlaque MD, Larrañaga N, Brennan P, Trichopoulos D, Trichopoulou A, Lagiou P, Hallmans G, Khaw KT, Key TJ, Riboli E, Canzian F. Kaaks R, et al. Among authors: kramer a. Int J Cancer. 2014 Nov 15;135(10):2475-81. doi: 10.1002/ijc.28874. Epub 2014 Apr 10. Int J Cancer. 2014. PMID: 24692151 Free article.
Germline genetics of cancer of unknown primary (CUP) and its specific subtypes.
Hemminki K, Chen B, Kumar A, Melander O, Manjer J, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Folprecht G, Löffler H, Krämer A, Försti A. Hemminki K, et al. Among authors: kramer a. Oncotarget. 2016 Apr 19;7(16):22140-9. doi: 10.18632/oncotarget.7903. Oncotarget. 2016. PMID: 26959888 Free PMC article.
Prediction of acute myeloid leukaemia risk in healthy individuals.
Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, Luben R, Hayat S, Wang TT, Zhao Z, Cirlan I, Pugh TJ, Soave D, Ng K, Latimer C, Hardy C, Raine K, Jones D, Hoult D, Britten A, McPherson JD, Johansson M, Mbabaali F, Eagles J, Miller JK, Pasternack D, Timms L, Krzyzanowski P, Awadalla P, Costa R, Segal E, Bratman SV, Beer P, Behjati S, Martincorena I, Wang JCY, Bowles KM, Quirós JR, Karakatsani A, La Vecchia C, Trichopoulou A, Salamanca-Fernández E, Huerta JM, Barricarte A, Travis RC, Tumino R, Masala G, Boeing H, Panico S, Kaaks R, Krämer A, Sieri S, Riboli E, Vineis P, Foll M, McKay J, Polidoro S, Sala N, Khaw KT, Vermeulen R, Campbell PJ, Papaemmanuil E, Minden MD, Tanay A, Balicer RD, Wareham NJ, Gerstung M, Dick JE, Brennan P, Vassiliou GS, Shlush LI. Abelson S, et al. Among authors: kramer a. Nature. 2018 Jul;559(7714):400-404. doi: 10.1038/s41586-018-0317-6. Epub 2018 Jul 9. Nature. 2018. PMID: 29988082 Free PMC article.
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, Kirchner M, Budczies J, Heukamp LC, Leichsenring J, Allgäuer M, Kazdal D, Löffler H, Weichert W, Schirmacher P, Stenzinger A, Krämer A. Bochtler T, et al. Among authors: kramer a. Int J Cancer. 2020 Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11. Int J Cancer. 2020. PMID: 31970771 Free article.
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP.
Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzschmar A, Köhne CH, Grünwald V, Hofheinz RD, Schütte K, Löffler H, Bokemeyer C, Krämer A; Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group. Folprecht G, et al. Among authors: kramer a. Br J Cancer. 2021 Feb;124(4):721-727. doi: 10.1038/s41416-020-01141-8. Epub 2020 Nov 25. Br J Cancer. 2021. PMID: 33235314 Free PMC article. Clinical Trial.
2,971 results